Newsfile Corp
25 Aug 2026, 21:44 UTC · 59m ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
A class action lawsuit alleges Capricor Therapeutics altered the statistical analysis plan for Deramiocel without prior FDA agreement before resubmitting its Biologics License Application. — Allegations of unauthorized changes to clinical data analysis suggest a high risk of FDA rejection for the company's primary cell therapy candidate.
-0.80The lawsuit claims there is a substantial risk to the regulatory approval of Deramiocel for the treatment of Duchenne muscular dystrophy. — Regulatory failure for a core pipeline product typically leads to significant devaluation of biotech equities.
-0.70The Rosen Law Firm is seeking a lead plaintiff for a securities class action regarding Capricor purchases made between December 17, 2025, and July 26, 2026. — While legal notices are common, the formalization of a class action introduces potential legal liabilities and settlement costs.
-0.20Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company is facing a securities class action lawsuit alleging materially false and misleading statements regarding FDA clinical data analysis.
The company is mentioned as being subject to a securities class action lawsuit.
The company is mentioned as being subject to a securities class action lawsuit.
TMX Group is mentioned as the news distributor and explicitly states it does not endorse the companies mentioned.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
5h ago
